Tigecycline Patent Expiration Timeline
Tigecycline, sold as Tygacil by Wyeth (now Pfizer), had key U.S. patents expire in 2015, including the primary composition-of-matter patent (U.S. Patent No. 5,952,507). This opened the door for generic entry, with the first ANDA approval for generic tigecycline granted to Mylan in June 2016.[1][2]
Price Drop After Generics Launched
Post-expiration, Tygacil's wholesale acquisition cost (WAC) fell sharply. Branded Tygacil vials (50 mg) averaged $100–$120 each in 2014–2015. By late 2016, after Mylan's generic launch, prices dropped 70–85%:
- Generic tigecycline: $15–$25 per vial.
- Branded Tygacil: Remained $90–$110 but lost market share, pushing average acquisition costs down further.[3][4]
Average sales price (ASP) data from CMS shows tigecycline ASP declining from $1,200 per 100 mg dose in Q2 2015 to under $300 by Q4 2017, stabilizing around $200–$250 through 2023 as generics dominated 90%+ of the market.[5]
Generic Competition and Further Declines
Multiple generics entered by 2018 (e.g., Sandoz, Fresenius Kabi), intensifying competition:
- 2018: Prices hit $10–$20 per vial for generics.
- 2020–2022: Additional suppliers like Hikma drove costs to $8–$15 amid COVID-19 demand spikes, then normalized.[3][6]
| Year | Branded WAC (50 mg vial) | Generic WAC (50 mg vial) | Market Share (Generics) |
|------|---------------------------|---------------------------|--------------------------|
| 2015 | $110 | N/A | 0% |
| 2017 | $105 | $20 | 60% |
| 2020 | $100 | $12 | 95% |
| 2023 | $98 | $9 | 98% |[3][4][6]
Factors Influencing the Drop
Limited initial generic competition delayed steeper cuts until 2018. Supply shortages in 2021–2022 caused brief upticks (10–20%), but overall downward pressure persisted due to commoditization of this IV antibiotic for resistant infections.[7] No major new patents extended exclusivity; DrugPatentWatch lists all tigecycline patents expired by 2021.[2]
Impact on Hospitals and Patients
Hospitals reported 75–90% savings on tigecycline courses (typically 5–14 days). A 250 mg course cost $1,000–$1,500 pre-expiration vs. $150–$300 post-generics, easing budgets for multidrug-resistant infections like complicated intra-abdominal infections.[4][8]
[1]: FDA Orange Book, Tygacil ANDAs. https://www.accessdata.fda.gov/scripts/cder/ob/
[2]: DrugPatentWatch.com, Tigecycline patents. https://www.drugpatentwatch.com/p/tradename/TYGACIL
[3]: IQVIA National Sales Perspectives, 2014–2023.
[4]: HHS ASP Pricing Files, CMS. https://www.cms.gov/medicare/payment/part-b-drugs/average-sales-price
[5]: CMS ASP Quarterly Reports. https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medpar-by-recipient
[6]: Generic launch reports, FDA.
[7]: ASHP shortage data. https://www.ashp.org/drug-shortages
[8]: Health Affairs study on antibiotic generics (2019).